Physician profile
Glenn Turett
NPI 1659409035
$252,600.64
in general payments reported to CMS, 2019-2025
20 companies · $50K in 2025
The $50K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $9,717 · 2021: $8,516 · 2022: $43K · 2023: $43K · 2024: $74K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Travel and Lodging: $12K · Food and Beverage: $6,195 · Consulting Fee: $3,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $145,250.00 |
| Travel and Lodging | $11,798.34 |
| Food and Beverage | $6,194.69 |
| Consulting Fee | $3,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $143,392.49 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $89,258.99 | 2019-2025 | Biktarvy, Sunlenca |
| Insmed, INC. | $11,539.41 | 2019-2021 | |
| Theratechnologies INC. | $2,880.23 | 2019-2025 | Trogarzo, Egrifta |
| Janssen Products, LP | $2,398.87 | 2019 | |
| Janssen Biotech, INC. | $1,991.26 | 2019-2023 | Symtuza |
| Melinta Therapeutics, LLC | $273.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $197.36 | 2019-2023 | Delstrigo, Pifeltro |
| Shionogi INC | $155.50 | 2021-2023 | Fetroja |
| Abbvie INC. | $93.35 | 2022-2023 | Dalvance |
| Paratek Pharmaceuticals, INC. | $89.20 | 2021-2025 | Nuzyra |
| Janssen Scientific Affairs, LLC | $69.39 | 2022-2023 | |
| Pfizer INC. | $54.96 | 2020-2021 | |
| Cumberland Pharmaceuticals, INC. | $50.60 | 2021-2023 | Vibativ |
| Daiichi Sankyo INC. | $49.38 | 2020-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Astellas Pharma US INC | $21.67 | 2022 | |
| Medtronic, INC. | $20.70 | 2024 | Signia |
| Philips North America LLC | $18.01 | 2021 | |
| Allergan, INC. | $17.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Turett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.